Policy & Regulation
Peptron IP License with NIH Supports Development of SR-exenatide for Treatment of Neurodegenerative Diseases
25 April 2018 - - Korea-based pharmaceutical company Peptron Inc. (087010: KS) has signed a new exclusive worldwide intellectual property license with the National Institute on Aging, part of the National Institutes of Health, an agency of the US Department of Health and Human Services,.
The exclusive license covers the delivery and use of sustained-release exenatide, a GLP-1 receptor agonist, in the treatment of neurodegenerative disorders, including Parkinson's and Alzheimer's diseases.
This intellectual property was developed as part of a Cooperative Research and Development Agreement (CRADA) between Peptron and the NIH to develop and advance a form of exenatide that effectively crosses the blood-brain barrier and provides sustained release of the neuroprotective peptide to treat degenerative diseases of the central nervous system.
Peptron has developed fundamental technologies for creating sustained-release formulations to develop patient-friendly peptide-based medicines with a high technological entrance barrier and excellent product competitiveness for the treatment of life-threatening and chronic diseases.
Peptron is headquartered in Daejeon, Korea with GMP manufacturing facilities in Osong, Korea.